Report - SAHGEED’ · 2 2 1 0 20 40 60 80 100 ’ 2 1 2 1 2 1 1 0 0 0 0 0 0 0 5,1mois 9,1mois Bevacizumab chez les sujets âgés - Etude de phase III AVEX MP. Saunders, et al., Lancet Oncol

Please pass captcha verification before submit form